Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Gregory M. Mayhew"'
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Patients with oral cavity squamous cell carcinoma (OCSCC) are predominantly human papillomavirus (HPV)(−), and treatment typically involves surgical resection ± neck dissection, followed by radiation ± chemotherapy. We previously described four m
Externí odkaz:
https://doaj.org/article/33bf6ffca9d14ee49feb01a110ac7a53
Autor:
Joel R. Eisner, Kirk D. Beebe, Gregory M. Mayhew, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jill Mooney, Michael V. Milburn, David Foureau, Richard L. White, Asim Amin, Marcos E. Milla
Publikováno v:
Cancer Research Communications. 2:894-903
Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation
Autor:
Joel R. Eisner, Gregory M. Mayhew, James M. Davison, Kirk D. Beebe, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jeffrey M. Conroy, Michael V. Milburn, David Neil. Hayes, Kathryn F. Mileham
Publikováno v:
Clinical Cancer Research.
Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic NS-NSCLC treated with pemetrexed-containing platinum doublet chemoth
Autor:
Marcos E. Milla, Asim Amin, Richard L. White, David Foureau, Michael V. Milburn, Jill Mooney, Joshua M. Uronis, Farhang Farhangfar, Carol Farhangfar, Yuelong Guo, Yoichiro Shibata, Gregory M. Mayhew, Kirk D. Beebe, Joel R. Eisner
Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aee2f498634f181e0903dde0904d827
https://doi.org/10.1158/2767-9764.c.6550872.v1
https://doi.org/10.1158/2767-9764.c.6550872.v1
Autor:
Marcos E. Milla, Asim Amin, Richard L. White, David Foureau, Michael V. Milburn, Jill Mooney, Joshua M. Uronis, Farhang Farhangfar, Carol Farhangfar, Yuelong Guo, Yoichiro Shibata, Gregory M. Mayhew, Kirk D. Beebe, Joel R. Eisner
this is a test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dcd889514c515c62aa335b1a1f130c0
https://doi.org/10.1158/2767-9764.22545183
https://doi.org/10.1158/2767-9764.22545183
Autor:
Marcos E. Milla, Asim Amin, Richard L. White, David Foureau, Michael V. Milburn, Jill Mooney, Joshua M. Uronis, Farhang Farhangfar, Carol Farhangfar, Yuelong Guo, Yoichiro Shibata, Gregory M. Mayhew, Kirk D. Beebe, Joel R. Eisner
40 gene IL-2 response classifier and related immune cell types
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e912be1d5a6174fc4d7074ca2edfe78
https://doi.org/10.1158/2767-9764.22545180
https://doi.org/10.1158/2767-9764.22545180
Autor:
Stephane Wenric, James M. Davison, John Guittar, Gregory M. Mayhew, Kirk D. Beebe, Yun E. Wang, Amrita A. Iyer, Hyunseok P. Kang, Michael V. Milburn, Vincent Chung, Tanios Bekaii-Saab, Charles M. Perou
BackgroundPancreatic ductal adenocarcinoma (PDAC) is amongst the deadliest cancers, with few modern tools to inform patient prognosis and help guide treatment options. Transcriptome-based molecular subtyping is one emerging technology that has been e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe5f2a6c4b61b76f6b921ebceead1bf2
https://doi.org/10.1101/2023.02.23.23286356
https://doi.org/10.1101/2023.02.23.23286356
Autor:
Stephane Wenric, James M. Davison, Yun E. Wang, Gregory M. Mayhew, Kirk Beebe, Hyunseok P. Kang, Michael V. Milburn, Vincent Chung, Tanios Bekaii-Saab, Charles M. Perou
Publikováno v:
Cancer Research. 82:A002-A002
Background: PDAC is a highly morbid disease with no validated biomarkers for first-line (1L) treatment selection. The PurIST single-sample molecular subtyping gene signature, initially described by Rashid et al. (Clin. Cancer Res., 2020), classifies
Autor:
Tracy L. Rose, William H. Weir, Gregory M. Mayhew, Yoichiro Shibata, Patrick Eulitt, Joshua M. Uronis, Mi Zhou, Matthew Nielsen, Angela B. Smith, Michael Woods, Michele C. Hayward, Ashley H. Salazar, Matthew I. Milowsky, Sara E. Wobker, Katrina McGinty, Michael V. Millburn, Joel R. Eisner, William Y. Kim
Publikováno v:
British Journal of Cancer. 126:1237-1237